A Randomized Trial of a Sphenopalatine Ganglion Block With Bupivacaine for Acute Headache

• Status: Not yet recruiting
• Trial end date: 2023-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to compare the administration and dosage of bupivacaine for sphenopalatine ganglion (SPG) nerve block. The main question[s] it aims to answer are:

• Does a high dose (3ml) give more relief than a low dose (1ml)?

• Does bilateral administration give more relief than unilateral? Participants with headaches will be asked to lie down and have SPG block performed.

Researchers will compare dosage and administration to see how symptoms are reduced.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• Present to ED for management of headache

• Headache is moderate or severe in intensity

Exclusion Criteria:

• Allergy to bupivacaine

• Nasal or sinus surgery